PCN44 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SPAIN
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)71940-4
https://www.valueinhealthjournal.com/article/S1098-3015(11)71940-4/fulltext
Title :
PCN44 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SPAIN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71940-4&doi=10.1016/S1098-3015(11)71940-4
First page :
A259
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
101